GLP-1

Ozempic Was Never Just a Weight-Loss Drug

📅 September 4, 2026 📂 AI & Machine Learning

GLP-1s are doing something far beyond weight loss and diabetes control: they appear to be modulating the immune system, with new data linking them to significantly fewer serious infections, including tuberculosis. This reframes these controversial drugs from metabolic luxury to potential broad-spectrum anti-infectives. But it exposes a brutal irony—the drug class that could fight diseases of poverty is priced like a status symbol, ensuring those most vulnerable to infection are the least likely to ever access it.

Drug Pricing GLP-1 Healthcare Access Obesity Drugs Ozempic

Amazon’s Weight-Loss Drug Move Isn’t About Obesity. It’s About Owning Healthcare.

📅 August 9, 2026 📂 Tech Industry

Amazon’s move to distribute GLP-1 weight-loss drugs through Medicare Part D looks like a play on the obesity trend. It’s not. It’s the first step in building a scalable pharmacy fulfillment infrastructure for chronic disease management — one that could make Amazon the default middleman for how America gets its prescriptions, reshaping drug pricing, patient access, and the entire pharmacy industry in the process.

Amazon Big Tech Drug Pricing GLP-1 Healthcare Logistics Medicare Pharmacy

The Skinny Premium Is a Lie. It Was Always a Fat Tax.

📅 August 8, 2026 📂 Tech Industry

The wage boost from weight loss was never about productivity. A new NBER study on GLP-1 drugs reveals that the ‘skinny premium’ was actually a stigma tax on people society judged as morally defective. As weight loss becomes medical rather than moral, the economic advantage of thinness may erode — exposing the discrimination that was there all along.

Body Weight Discrimination GLP-1 Labor Market Obesity Social Judgment Stigma Wage Gap